Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
复制标题
DOI：
10.1373/clinchem.2005.058198
复制
发表时间：
2006-04-01
影响因子：
9.3
通讯作者：
Harper, P
中科院分区：
文献类型：
--
作者：
Floderus, Y;Sardh, E;Harper, P
Background: The heme precursors porphobilinogen (PBG) and 5-aminolevulinic acid (ALA) accumulate during overt crises of acute intermittent porphyria (AIP), and high excretion of these metabolites often continues in the asymptomatic phase.Methods: We measured concentrations of PBG and ALA and investigated the correlation between these metabolites in plasma and urine in 10 asymptomatic All? carriers with high excretion and in 5 healthy individuals. We quantified plasma concentrations with an HPLC-mass spectrometric method and urine concentrations with ion-exchange chromatography.Results: The mean (SD) plasma concentrations of PBG and ALA in the All? carriers were 3.1 (1.0) and 1.7 (0.7) mu mol/L, respectively. The mean 8-h urinary excretion amounts of PBG and ALA in the AIP carriers were 102 (25) and 56 (18) mu mol, respectively, whereas the corresponding values for healthy individuals were 2.9 (0.7) and 9.3 (1.2) mu mol. The correlations between PBG and ALA values in plasma and urine of the All? carriers were 0.678 and 0.856, respectively. The mean PBG/ALA ratio was similar to 2.0 in both plasma and urine for the AIP carriers and 0.3 in urine for the healthy individuals. The renal clearance rates for PBG and ALA were 71 (15) and 70 (13) mL/min, respectively.Conclusions: The described HPLC-mass spectrometric method enabled characterization of variations in plasma PBG and ALA in All? carriers during an 8-h period. The renal clearances were similar for both metabolites. This method could be used to monitor All? patients during treatment. (c) 2006 American Association for Clinical Chemistry.
